| abstract |
The present disclosure is generally directed to compositions that include antibodies, e.g ., monoclonal, chimeric, humanized antibodies, antibody fragments, etc ., that specifically bind on or more epitopes within a Siglec-9 protein, e.g ., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. |